PSME2P2: A Promising Drug Target and Biomarker for Proteasome-Mediated Diseases

Target Name: PSME2P2

NCBI ID: G338099

Other Name(s): Proteasome activator subunit 2 pseudogene 2 | proteasome activator subunit 2 pseudogene 2

PSME2P2: A Promising Drug Target and Biomarker for Proteasome-Mediated Diseases

Proteasomes are key intracellular organelles responsible for regulating protein degradation and cell survival. They play a crucial role in fighting against various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The study of proteasomes has led to the discovery of numerous potential drug targets and biomarkers. In this article, we will focus on PSME2P2, a pseudogene that has been shown to interact with proteasomes and has the potential to be a drug target or biomarker for several proteasome-mediated diseases.

PSME2P2: Structure and Function

PSME2P2 is a 21-kDa protein that belongs to the PSME family. This family is known for their ability to interact with the proteasome and regulate its activity. PSME2P2 functions as a protein activator of the proteasome, which means that it promotes the formation of proteasomes and activates their activity.

The structure of PSME2P2 is highly conserved across various species, including humans. It consists of a unique N-terminus, a transmembrane region, and a C-terminus. The N-terminus of PSME2P2 contains a putative N-endopeptide loop, which is involved in the formation of a complex with the proteasome. The transmembrane region is known for its acidic and basic residues, which are involved in the regulation of the proteasome's activity. The C-terminus of PSME2P2 contains a single amino acid residue that is involved in the formation of a disulfide bond, which is necessary for protein stability.

PSME2P2 has been shown to play a crucial role in the regulation of proteasome-mediated diseases. Studies have shown that PSME2P2 can promote the formation of proteasomes, which are then involved in the degradation of specific proteins. This process is known as \"proteasome-mediated degradation\" or \"proteasome-driven degradation.\"

One of the well-known functions of PSME2P2 is its role in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which is thought to be caused by the accumulation of damaged or misfolded proteins. Studies have shown that PSME2P2 can be used as a potential drug target to treat neurodegenerative diseases by inhibiting the activity of the proteasome.

Another promising application of PSME2P2 is its potential as a biomarker for cancer. Cancer is characterized by the rapid accumulation of damaged or misfolded proteins, which can lead to the formation of cancer cells. Studies have shown that PSME2P2 can be used as a potential biomarker for cancer by detecting the level of its expression in cancer cells. This approach could help in the development of new cancer therapies that specifically target PSME2P2.

PSME2P2 Interactions with Other Proteasome Proteins

PSME2P2 is not a solitary protein that operates alone. It functions as part of a complex with several other proteins, including the 26S proteasome subunit alpha (26S-alpha), which is the major subunit of the proteasome responsible for protein degradation. The complex formed by PSME2P2 and 26S-alpha consists of several subunits, including the 23S subunit, the 18S subunit, and the 5S subunit.

The activity of PSME2P2 is regulated by several factors, including the concentration of other proteins in the system, such as the levels of

Protein Name: Proteasome Activator Subunit 2 Pseudogene 2

More Common Targets